☆ 4.8 Letter

Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea

CIRCULATION (2018)

Journal

CIRCULATION

Volume 138, Issue 6, Pages 646-648

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1161/CIRCULATIONAHA.118.034489

Keywords

adenosine; dyspnea; P2Y(12) receptors; ticagrelor

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Funding

Erasmus Medical Center
AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Pharmacology & Pharmacy

Purinergic signaling in diabetes and metabolism

Shanu Jain, Kenneth A. Jacobson

Summary: Purinergic signaling, originally proposed by Geoffrey Burnstock, plays a crucial role in modulating pathways in various physiological systems. Adenosine receptors and P2 nucleotide receptors are involved in metabolic disorders, affecting specific cell types like adipocytes, skeletal muscle, liver cells, and immune cells. Selective ligands for adenosine and P2 receptors may have therapeutic potential for diabetes and obesity, but conflicting conclusions exist in drug discovery related to this topic.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report

Daniel Cesarini, Iacopo Muraca, Martina Berteotti, Anna Maria Gori, Andrea Sorrentino, Alessia Bertelli, Rossella Marcucci, Renato Valenti

Summary: Ticagrelor is a recommended medication for DAPT in ACS patients, but it is associated with increased risk of dyspnea and bradyarrhythmias. The molecular mechanisms of these side effects and their management strategies are not well-defined. This article presents a case report and reviews the available evidence to propose decision-making algorithms for managing these side effects in clinical practice.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Purinergic Signalling in the Cochlea

Srdjan M. M. Vlajkovic, Peter R. R. Thorne

Summary: The mammalian cochlea, as the sensory organ for hearing, is regulated by ATP release and adenosine signaling, triggering various physiological responses and playing important roles in cochlear development, homeostasis, and sensory transduction. Understanding these mechanisms may provide therapeutic strategies for cochlear rescue and prevention of hearing loss.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Pharmacology & Pharmacy

Early evolutionary history (from bacteria to hemichordata) of the omnipresent purinergic signalling: A tribute to Geoff Burnstock inquisitive mind

Alexei Verkhratsky

Summary: Purines and pyrimidines are essential molecules for genetic code and bioenergetics. Through evolution, purines have been associated with damage-related extracellular signaling, while plants have developed a sophisticated purinergic signaling system. In vertebrates, the purinergic signaling system operates universally without anatomical or functional segregation.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

From astrocytes to satellite glial cells and back: A 25 year-long journey through the purinergic modulation of glial functions in pain and more

Stefania Ceruti

Summary: Progress in pain research has focused on the role of glial cells and purinergic receptors in pain modulation. Understanding the purinergic system's involvement in pain conditions may lead to the development of new and effective analgesics.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus

Dawid Polak, Marcin Talar, Nina Wolska, Dagmara W. Wojkowska, Kamil Karolczak, Karol Kramkowski, Tomasz A. Bonda, Cezary Watala, Tomasz Przygodzki

Summary: The A(2A) agonist HE-NECA in low doses in combination with inhibitors of P2Y(12) improved anti-thrombotic properties and was effective with chronic administration. Additionally, HE-NECA has hypotensive effects but does not significantly affect blood-brain barrier permeability.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Pharmacology & Pharmacy

Ticagrelor inverse agonist activity at the P2Y(12) receptor is non-reversible versus its endogenous agonist adenosine 5'-diphosphate

Jawad Khalil, Tudor Dimofte, Timothy Roberts, Michael Keith, Kumuthu Amaradasa, Matthew S. Hindle, Sukhinder Bancroft, James L. Hutchinson, Khalid Naseem, Thomas Johnson, Stuart J. Mundell

Summary: This study found that the binding of ticagrelor to the P2Y(12) receptor is prolonged and more similar to that of an irreversible antagonist. This highlights the clinical need for novel ticagrelor reversal strategies in patients with bleeding.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Add to Collection

Article Cell Biology

Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel

Karla N. Samman, Pamela Mehanna, Emad Takla, Jean-Christophe Grenier, Mark Y. Chan, Renato D. Lopes, Megan Lee Neely, Tracy Y. Wang, L. Kristin Newby, Richard C. Becker, Marie Lordkipanidze, Matthieu Ruiz, Julie G. Hussin, E. Marc Jolicoeur

Summary: Untargeted metabolomics identified signature fatty acids related to cardiovascular disease biomarkers, providing important insights into evaluating differential treatment response in myocardial infarction patients.

CELL REPORTS MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Purinergic transmission in depressive disorders

Aleksandra Szopa, Katarzyna Socala, Anna Serefko, Urszula Doboszewska, Andrzej Wrobel, Ewa Poleszak, Piotr Wlaz

Summary: Purinergic signaling plays a significant role in depression, with studies suggesting altered adenosine metabolism in depressed patients may serve as a disease biomarker. Research also indicates that manipulation of P1 or P2 receptors, along with selective or nonselective ligands, can impact the development and progression of depression.

PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Review Neurosciences

Purinergic receptors in cognitive disturbances

Peter Illes, Henning Ulrich, Jiang-Fan Chen, Yong Tang

Summary: Purinergic receptors of the ATP/ADP, UTP/UDP and adenosine-sensitive classes play a broad role in cognitive processes, both in normal and disease conditions. Neurodegenerative diseases are associated with the release of high concentrations of ATP, which is enzymatically degraded to adenosine. Activation of P2X7 and A2AR receptors on various protein aggregates contributes to the primary injury, and small molecular antagonists show promise in preventing or mitigating this damage in animal models. Purinergic receptors are also implicated in psychiatric diseases, suggesting their potential as therapeutic targets for cognitive deterioration.

NEUROBIOLOGY OF DISEASE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial

Himawan Fernando, Thy Duong, Kevin Huynh, Jonathan Noonan, James Shaw, Stephen J. Duffy, Ziad Nehme, Karen Smith, Paul S. Myles, Peter J. Meikle, Karlheinz Peter, Dion Stub

Summary: This study evaluated the impact of intravenous fentanyl and lignocaine on the pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina and non-ST-elevation myocardial infarction. The results showed that lignocaine does not impair the bioavailability or delay the antiplatelet effect of ticagrelor, and both drugs were well tolerated with a high level of patient satisfaction.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Pharmacology & Pharmacy

The P2Y/P2X divide: How it began

Charles Kennedy

Summary: Extracellular purine and pyrimidine nucleotides produce pharmacological effects through P2 receptors, which are divided into P2X and P2Y families based on pharmacological criteria. Progress in cloning and high resolution imaging has provided insights into how agonists and antagonists bind to receptors, leading to changes in receptor conformation and activity. This has led to the development of subtype-selective agonists and antagonists, some of which are now in clinical use, showcasing the foresight and drive of Geoff Burnstock in advancing the field.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Purinergic Regulation of Endothelial Barrier Function

Muhammad Aslam, Dursun Gunduz, Christian Troidl, Jacqueline Heger, Christian W. Hamm, Rainer Schulz

Summary: This review discusses the influence of activation of various purinergic receptors and downstream signaling pathways on vascular permeability during pathological conditions, noting that the effects may depend on the type and prevalence of activated receptors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

Dominick J. Angiolillo, Davide Cao, Samantha Sartori, Usman Baber, George Dangas, Zhongjie Zhang, Birgit Vogel, Vijay Kunadian, Carlo Briguori, David J. Cohen, Timothy Collier, Dariusz Dudek, Michael Gibson, Robert Gil, Kurt Huber, Upendra Kaul, Ran Kornowski, Mitchell W. Krucoff, Alfonso Ielasi, Giulio G. Stefanini, Carlo A. Pivato, Shamir Mehta, David J. Moliterno, E. Magnus Ohman, Javier Escaned, Gennaro Sardella, Samin K. Sharma, Richard Shlofmitz, Giora Weisz, Bernhard Witzenbichler, P. Gabriel Steg, Stuart Pocock, Roxana Mehran

Summary: This study found that nearly 10% of patients receiving ticagrelor therapy experienced dyspnea-related discontinuation of treatment. Asian race, smoking, prior PCI, and other factors were identified as predictors of dyspnea-related ticagrelor discontinuation. Ticagrelor monotherapy after discontinuation did not increase the risk of subsequent cardiovascular events.

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

Add to Collection

Article Immunology

Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12signaling pathway

Bo Huang, Yufeng Qian, Shujun Xie, Xianhua Ye, Hanwen Chen, Zhifeng Chen, Lihuan Zhang, Jinming Xu, Hu Hu, Shenglin Ma, Paul Heroux, Di Wang, Han-Ming Shen, Yihua Wu, Dajing Xia

Summary: Ticagrelor, a reversible P2Y(12) receptor antagonist, has been approved for coronary artery disease treatment. It was found to inhibit NLRP3 inflammasome activation in macrophages, independent of its inhibition on the P2Y(12) signaling pathway. Mechanistic studies show that ticagrelor attenuates ASC oligomerization by blocking chloride efflux.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Oral P2Y12 inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot

Mattia Galli, Luis Ortega-Paz, Dominick J. Angiolillo

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor The Switching Antiplatelet (SWAP)-5 Study

Francesco Franchi, Luis Ortega-Paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou Md, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Birgit Reiter, Bernd Jilma, Dominick J. Angiolillo

Summary: This study aimed to evaluate the potential drug-drug interaction between cangrelor and ticagrelor in patients who have been pretreated with ticagrelor. The results showed that adding cangrelor to ticagrelor-treated patients significantly reduced platelet reactivity, and there were no differences in platelet inhibition after discontinuation of drug infusion, indicating the absence of a drug-drug interaction.

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction

Luis Ortega-Paz, Helena Cristobal, Jose Tomas Ortiz-Perez, Pablo Garcia de Frutos, Guiomar Mendieta, Elena Sandoval, Juan Jose Rodriguez, Emilio Ortega, Ana Garcia-Alvarez, Salvatore Brugaletta, Manel Sabate, Ana Paula Dantas

Summary: In-vitro experiments on myocardial fibroblasts from patients with HFrEF found that Dapagliflozin alone dose-dependently slowed migration of the fibroblasts, and the combination of Dapagliflozin + LCZ696 further reduced migration rate, while Dapagliflozin + spironolactone altered the effects of SGLT2i on biomarkers.

ESC HEART FAILURE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials

Francesco Costa, Claudio Montalto, Mattia Branca, Sung-Jin Hong, Hirotoshi Watanabe, Anna Franzone, Pascal Vranckx, Joo-Yong Hahn, Hyeon-Cheol Gwon, Fausto Feres, Yangsoo Jang, Giuseppe De Luca, Elvin Kedhi, Davide Cao, Philippe Gabriel Steg, Deepak L. Bhatt, Gregg W. Stone, Antonio Micari, Stephan Windecker, Takeshi Kimura, Myeong-Ki Hong, Roxana Mehran, Marco Valgimigli

Summary: The study evaluated the impact of an abbreviated dual antiplatelet therapy (DAPT) regimen in high bleeding risk patients after percutaneous coronary intervention (PCI), using existing evidence. It found that a shorter DAPT duration (1-3 months) reduced bleeding and cardiovascular mortality without increasing ischemic events in these patients.

EUROPEAN HEART JOURNAL (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Sailing in the complexity of the 'shark-fin' sign

Antonio Landi, Anna Giulia Pavon, Marco Valgimigli

HEART (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials

Claudio Montalto, Francesco Costa, Sergio Leonardi, Antonio Micari, Jacopo A. Oreglia, Pascal Vranckx, Davide Capodanno, Jurrien ten Berg, Renato D. Lopes, Marco Valgimigli

Summary: In patients with concomitant indication to oral anticoagulation, shortening dual antiplatelet therapy duration can reduce bleeding risk without increasing major adverse cardiovascular events.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Antithrombotic therapy in patients with established atherosclerotic coronary disease

Antonio Landi, Marco Valgimigli

HEART (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Abbreviated or Standard Antiplatelet Therapy in HBR Patients Final 15-Month Results of the MASTER-DAPT Trial

Antonio Landi, Dik Heg, Enrico Frigoli, Pascal Vranckx, Stephan Windecker, Patrick Siegrist, Guillaume Cayla, Adrian Wlodalczak, Stephane Cook, Ivan Gomez-Blazquez, Yair Feld, Park Seung-Jung, Martin Mates, Chaim Lotan, Sengottuvelu Gunasekaran, Mamoru Nanasato, Rajiv Das, Henning Kelbaek, Emmanuel Teiger, Javier Escaned, Yuki Ishibashi, Gilles Montalescot, Hitoshi Matsuo, Dragan Debeljacki, Pieter C. Smits, Marco Valgimigli

Summary: This study investigated the clinical outcomes and treatment selection of antiplatelet therapy (APT) after percutaneous coronary intervention (PCI). The results showed that there was no difference in net adverse clinical outcomes and major adverse cardiac and cerebral events between abbreviated and standard APT at 15 months, but abbreviated APT had a lower risk of bleeding.

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy

Antonio Landi, Adrian Wlodarczak, Ralph Tolg, Henning Kelbaek, Jacek Legutko, Stefano Galli, Matthieu G. Godin, Gabor G. Toth, Thibault Lhermusier, Benjamin Honton, Peter Laurenz Dietrich, Francis Stammen, Bert Ferdinande, Johanne Silvain, Davide Capodanno, Guillaume Cayla, Marco Valgimigli

Summary: The BIOFLOW-DAPT trial is investigating the safety of the Orsiro Mission stent compared to the Resolute Onyx stent in high bleeding risk patients. Patients are initially treated with one month of dual antiplatelet therapy (aspirin and a P2Y(12) inhibitor), followed by single antiplatelet therapy. The primary endpoint is the occurrence of cardiac death, myocardial infarction, and stent thrombosis within one year.

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease

Marco Valgimigli, Victor Aboyans, Dominick Angiolillo, Dan Atar, Davide Capodanno, Sigrun Halvorsen, Stefan James, Peter Juni, Vijay Kunadian, Antonio Landi, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Eliano Pio Navarese, Josef Niebauer, Angelo Oliva, Raffaele Piccolo, Susanna Price, Robert F. Storey, Heinz Voeller, Pascal Vranckx, Stephan Windecker, Keith A. A. Fox

Summary: Multiple guidelines and consensus papers have been used to address the role of antithrombotic strategies in patients with established coronary artery disease (CAD). To update clinicians on the best antithrombotic strategies for these patients, the authors conducted a consensus initiative. They systematically reviewed and performed meta-analyses using both direct and indirect comparisons to inform their recommendations.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)

Eliano Pio Navarese, Antonio Landi, Angelo Oliva, Raffaele Piccolo, Victor Aboyans, Dominick Angiolillo, Dan Atar, Davide Capodanno, Keith A. A. Fox, Sigrun Halvorsen, Stefan James, Peter Juni, Vijay Kunadian, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Josef Niebauer, Susanna Price, Robert F. Storey, Heinz Voller, Pascal Vranckx, Stephan Windecker, Marco Valgimigli

Summary: Two network meta-analyses were conducted to evaluate all available antithrombotic treatments within or after 12 months following coronary revascularization and/or acute coronary syndrome. Ticagrelor monotherapy showed lower cardiovascular mortality risk within 12 months, and P2Y(12) monotherapy, especially ticagrelor, was associated with lower risk of myocardial infarction beyond 12 months. Aspirin and rivaroxaban 2.5 mg were most effective in reducing stroke risk, with a more acceptable bleeding risk than VKA.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial

Marco Valgimigli, Adrian Wlodarczak, Ralph Toelg, Bela Merkely, Henning Kelbaek, Jacek Legutko, Stefano Galli, Matthieu Godin, Gabor G. Toth, Thibault Lhermusier, Benjamin Honton, Peter Laurenz Dietrich, Francis Stammen, Bert Ferdinande, Johanne Silvain, Davide Capodanno, Guillaume Cayla

Summary: This study aimed to compare the safety and effectiveness of biodegradable-polymer sirolimus-eluting stents with durable-polymer zotarolimus-eluting stents in patients at high bleeding risk receiving abbreviated dual antiplatelet therapy after percutaneous coronary intervention (PCI). The results showed that the use of biodegradable-polymer sirolimus-eluting stents was noninferior to the use of durable-polymer zotarolimus-eluting stents in terms of the composite outcome of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year.

CIRCULATION (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Vascular Access in Percutaneous Coronary Intervention of Chronic Total Occlusions: A State-of-the-Art Review

Thomas A. Meijers, Adel Aminian, Marco Valgimigli, Joseph Dens, Pierfrancesco Agostoni, Juan F. Iglesias, Gabriele L. Gasparini, Arnold H. Seto, Shigeru Saito, Sunil V. Rao, Niels van Royen, Emmanouil S. Brilakis, Maarten A. H. van Leeuwen

Summary: The outcomes of chronic total occlusion percutaneous coronary intervention have significantly improved in the past decade, with a focus on improving procedural safety. Vascular access site bleeding is a common complication, and various strategies have been implemented to reduce its occurrence. This state-of-the-art review provides an overview of the current evidence on optimal vascular access strategies for chronic total occlusion percutaneous coronary intervention.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

Alessandro Spirito, Marco Valgimigli, Davide Cao, Usman Baber, Shamir R. Mehta, C. Michael Gibson, Gabriel P. Steg, Samin K. Sharma, Ridhima Goel, Kurt Huber, Vijay Kunadian, Javier Escaned, Anna Franzone, Han Yaling, Timothy Collier, Upendra Kaul, Ran Kornowski, Mitchell Krucoff, David Moliterno, Samantha Sartori, Ruth Owen, Zhongjie Zhang, George D. Dangas, Adnan Kastrati, Dominick J. Angiolillo, David J. Cohen, Pascal Vranckx, Stephan Windecker, Stuart Pocock, Roxana Mehran

Summary: BP-BES is associated with lower risk of major adverse cardiovascular events and target-vessel failure compared to other current generation LES in ACS patients.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2023)

Add to Collection

Meeting Abstract Cardiac & Cardiovascular Systems

Reproducibility of an Artificial Intelligence Optical Coherence Tomography Software for Tissue Characterization: Implications for the Design of Longitudinal Studies

Mohil Garg, Hector M. Garcia-Garcia, Andrea Teira Calderon, Jaytin Gupta, Shrayus Sortur, Molly B. Levine, Andrea Picchi, Gennaro Sardella, Marianna Adamo, Enrico Frigoli, Ugo Limbruno, Stefano Rigattieri, Roberto Diletti, Giacomo Boccuzzi, Marco Zimarino, Marco Contarini, Filippo Russo, Paolo Calabro, Giuseppe Ando, Ferdinando Varbella, Stefano Garducci, Cataldo Palmieri, Carlo Briguori, Jorge Sanz Sanchez, Marco Valgimigli

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.